Producer
Pall Corporation (Danaher subsidiary)
American filtration, separation, and purification technology company (Port Washington, NY; Danaher Corporation subsidiary since 2015 acquisition for $13.8B); world's second-largest pharmaceutical sterilizing filter manufacturer under the Supor® (PES), Fluorodyne® EX (PVDF), and Emflon® (PTFE) brands. Pall Corporation was founded in 1946 by Dr. David Pall, a British-born scientist who invented the first practical fluid filtration membrane for aircraft jet fuel systems during WWII — technology originally developed for military aviation now forms the basis of pharmaceutical sterile filtration. Pall's acquisition by Danaher — which also owns Cytiva (former GE Healthcare Life Sciences, bioreactors and chromatography) — means a single US conglomerate controls approximately 35-40% of the critical tools and materials used in both IV fluid manufacturing and biopharmaceutical drug production.
3
Inputs supplied
3
Goods downstream
1
Facilities
0
Stories
What they make
3 inputs Pall Corporation (Danaher subsidiary) supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
manufactured
0.22-Micron Sterilizing-Grade Membrane Filters →
manufactured
0.22-μm Sterilizing-grade Membrane Filters (PVDF/PTFE/PES) →
manufactured
PVDF and polysulfone hollow fiber ultrafiltration membranes →
Where it shows up
Goods downstream
Essential goods that depend on something Pall Corporation (Danaher subsidiary) makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Pharmaceutical Sterilizing Filters
35%Bioprocessing Filters & Systems
25%Industrial Filtration (Aerospace, Semiconductor)
25%Laboratory & Food/Beverage Filtration
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Origin2023
Pall Corporation was founded in 1946 by Dr. David Pall, a British-born scientist who had developed the first practical fluid filtration membrane for aircraft jet fuel systems during WWII -- solving the problem of water and particulate contamination in high-altitude aircraft engines. Dr. David Pall's WWII aircraft fuel filter was the founding technology: a membrane small enough to remove particulates from fuel while allowing liquid flow at operational pressures. After the war, Pall recognized that the same membrane technology could be applied to pharmaceutical manufacturing -- and founded his company in Port Washington, New York to commercialize both aerospace and pharmaceutical filtration. By the time Danaher acquired Pall for $13.8B in 2015, Pall had become the second-largest pharmaceutical sterilizing filter company globally. The WWII military aviation filter that kept Spitfires and B-17s running also became the membrane protecting every IV solution from bacterial contamination -- a direct, traceable technology lineage from military aviation to hospital pharmacy.
Pall Corporation (Danaher) ↗Did you know2023
Pall Corporation filters are used in pharmaceutical IV solution sterilization (0.22µm bioburden reduction for IV bags), semiconductor ultrapure water systems (sub-micron particle removal for chip fabs), aircraft fuel systems (particulate and water removal for jet engines), and food and beverage sterile filtration (wine and beer clarification, bottled water production). The same membrane filtration technology -- modified for different materials of construction, pore sizes, and validation requirements -- serves hospital pharmacy, semiconductor manufacturing, aviation, and food production. A Pall manufacturing quality hold, an intellectual property dispute (Danaher has faced patent challenges from Sartorius and Merck Millipore), or a Danaher corporate divestiture decision affecting Pall would simultaneously affect pharmaceutical IV production capability, semiconductor UPW system maintenance, aircraft fuel system filter supply, and food/beverage sterile filtration across four industries that have no common supply chain monitoring.
Pall Corporation (Danaher) ↗Concentration2023
Danaher Corporation (Washington DC; NYSE: DHR; $30B revenue) acquired Pall Corporation in 2015 for $13.8B and GE Healthcare Life Sciences (renamed Cytiva) in 2020 for $21.4B — giving a single US conglomerate control over: Pall's sterilizing filters and bioprocessing filters, Cytiva's bioreactors, chromatography resins, and cell culture media. Combined, Pall+Cytiva means that a US industrial conglomerate controls the sterilizing filters, the bioreactors, and the chromatography equipment used in the vast majority of biopharmaceutical drug manufacturing worldwide. Danaher's business model — acquiring scientific instrument and life science companies and implementing the 'Danaher Business System' (lean manufacturing) — has assembled the world's most comprehensive portfolio of biopharmaceutical manufacturing enabling equipment. FDA regulations requiring that manufacturers validate each supplier's specific equipment create structural lock-in: once a vaccine or IV fluid facility qualifies Pall filters and Cytiva bioreactors, switching competitors costs years of revalidation.
Danaher Corporation ↗